The potential impact of preventive HIV vaccines in China: Results and benefits of a Multi-Province modeling collaboration

Vaccines

Volumn 3, Issue 1, 2015, Pages

  Harmon, Thomas ^a   Guo, Wei ^b   Stover, John ^c   Wu, Zunyou ^b   Kaufman, Joan ^d   Schneider, Kammerle ^e   Liu, Li ^f   Feng, Liao ^f   Schwartländer, Bernard ^g  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c AVENIR HEALTH   (United States)

^d East Asia ^*  (China)

^e PATH   (United States)

^f Center for Disease Control and Prevention of Sichuan Province   (China)

^g UNAIDS   (Switzerland)

Author keywords

China; HIV AIDS; Modeling; Prevention; Research; Sichuan; Vaccines

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; CHINA; CLINICAL EFFECTIVENESS; DEVELOPING COUNTRY; DISEASE MODEL; DISEASE PREDISPOSITION; EPIDEMIC; FINANCIAL MANAGEMENT; GEOGRAPHIC DISTRIBUTION; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION RISK; MORTALITY; PREVENTIVE MEDICINE; PUBLIC HEALTH; RISK ASSESSMENT; VACCINATION; VIRUS INFECTIVITY;

EID: 85016848959     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines3010001     Document Type: Article

References (23)

1. National Intelligence Council. The Next Wave of HIV/AIDS: Nigeria, Ethiopia, Russia, India and China; Washington, DC, USA, 2002; pp. 24-25.
2. Joint United Nations Programme on HIV/AIDS. Meeting the Investment Challenge: Tipping the Dependency Balance; Geneva, Switzerland, 2012; pp. 1-3.
3. Reuters "China Says HIV/AIDS Cases Up, Premier-in-Waiting Promises Help." Available online: http://www.reuters.com/article/2012/11/28/us-china-aids-idUSBRE8AR0G820121128 (accessed on 28 November 2012).
4. Ministry of Health of China. 2012 China AIDS Response Progress Report; Beijing, China, 2012.
5. Cohen, M.S.; Chen, Y.Q.; McCauley, M.; Gamble, T.; Hosseinipour, M.C.; Kumarasamy, N.; Hakim, J.G.; Kumwenda, J.; Grinsztejn, B.; Pilotto, J.H.; et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 2011, 365, 493-505.
6. British Columbia Centre for Excellence in HIV/AIDS China. Implements BC-CfE's Treatment as Prevention Strategy as the Country's National HIV/AIDS Policy. Available online: http://www.cfenet. ubc.ca/news/releases/china-implements-bc-cfe%E2%80%99s-treatment-prevention-strategy-country%E2%80%99s-national-hivaids-pol (accessed on 18 November 2012).
7. Scientists See AIDS Vaccine Within Reach after Decades. Available online: http://www.reuters.com/ article/2012/07/15/us-aids-vaccines-idUSBRE86E09C20120715 (accessed on 15 July 2012).
8. International AIDS Vaccine Initiative. The Impact of an AIDS Vaccine in Developing Countries: A New Model and Preliminary Results, Policy Research Working Paper #8; New York, NY, USA, 2006.
9. International AIDS Vaccine Initiative. The Potential Impact of an AIDS Vaccine in Low- and Middle-Income Countries, Policy Brief 29; New York, NY, USA, 2012.
10. Fonseca, M.G.P.; Forsythe, S.; Menezes, A.; Vuthoori, S.; Possas, C.; Veloso, V.; de Fátima Lucena, F.; Stover, J. Modeling HIV vaccines in Brazil: Assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV. PLOS ONE 2010, 5, e11736.
11. International AIDS Vaccine Initiative. Kenya: Estimating the Potential Impact of an AIDS Vaccine, Policy Brief 24, 2009; New York, NY USA, 2009.
12. International AIDS Vaccine Initiative. Uganda: Estimating the Potential Impact of an AIDS Vaccine, Policy Brief 22; New York, NY, USA, 2009.
13. Stover, J.; Brown, T.; Marston, M. Updates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children. Sex Trans. Infect. 2012, 88, i11-ii16.
14. Stover, J.; Bollinger, L.; Hecht, R.; Williams, C.; Roca, E. The impact of an AIDS vaccine in developing countries: A new model and initial results. Health Aff. 2007, 26, 1147-1158.
15. Bollinger, L.A. How can we calculate the "E" in "CEA"? AIDS 2008, 22, S51-S57.
16. The illustrative introduction of an effective HIV vaccine in the model in 2020 does not convey a prediction on behalf of the authors that a licensable vaccine will be available in 2020.
17. Bailey, R.C.; Moses, S.; Parker, C.B.; Agot, K.; Maclean, I.; Krieger, J.N.; Williams, C.F.; Campbell, R.T.; Ndinya-Achola, J.O. Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet 2007, 369, 643-656.
18. Kong, X.; Kigozi, G.; Nalugoda, F.; Musoke, R.; Kagaayi, J.; Latkin, C.; Ssekubugu, R.; Lutalo, T.; Nantume, B.; Boaz, I.; et al. Assessment of changes in risk behaviors during 3 years of posttrial follow-up of male circumcision trial participants uncircumcised at trial closure in Rakai, Uganda. Am. J. Epidemiol. 2012, 176, 875-885.
19. Liddon, N.C.; Leichliter, J.S.; Markowitz, L.E. Human papillomavirus vaccine and sexual behavior among adolescent and young women. Am. J. Prev. Med. 2012, 42, 44-52.
20. World Health Organization. Global HIV/AIDS Response, Epidemic Update and Health Sector Progress towards Universal Access 2011 Progress Report; Geneva, Switzerland, 2011.
21. This figure is calculated using the 2010 prices of ART for low- and middle-income countries of $155 for first-line and $1678 for second-line [WHO, Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector, Progress Report 2010, WHO, UNAIDS, UNICEF] and assuming that prices for second line ART decline to $980 by 2015. The cost of diagnostics and monitoring tests is $180 per patient, per year and the service delivery costs are $176 per patient, per year [Stover J, Bollinger L, Avila C. Estimating the Impact and Cost of the WHO 2010 Guidelines for Antiretroviral Therapy, AIDS Research and Treatment, Vol 2011, Article ID 738271, doi:10.1155/2011/738271]. Need for treatment begins eight years after infection and annual survival on first and second line is assumed to be 92% to 99% depending on the patient's CD4 count at treatment initiation (IeDEA Consortium). With these assumptions a typical patient survives for about 28 years on first-line treatment and 12 years on second-line. All costs are discounted at 3% per year to the time of infection. For more information, see the interactive ART costs calculator, which can be accessed through the "Policy Tools" link on the Futures Institute website, www.FuturesInstitute.org.
22. HIV Vaccine Enters Second Phase of Testing on Volunteers. Available online: http: //www.chinadaily. com.cn/cndy/2012-08/15/content_15676479.htm (accessed on 15 August 2012).
23. IAVI. Opportunities for Accelerating AIDS Vaccine R&D in China, Policy Brief 27; New York, NY, USA, 2011.